tanshinone ii a has been researched along with candesartan in 2 studies
| Studies (tanshinone ii a) | Trials (tanshinone ii a) | Recent Studies (post-2010) (tanshinone ii a) | Studies (candesartan) | Trials (candesartan) | Recent Studies (post-2010) (candesartan) |
|---|---|---|---|---|---|
| 61 | 0 | 41 | 1,929 | 412 | 589 |
| Protein | Taxonomy | tanshinone ii a (IC50) | candesartan (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 3.2769 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 5.9472 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 3.0652 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 9 | |
| Adenosine receptor A3 | Homo sapiens (human) | 1.2199 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 3 | |
| Beta-3 adrenergic receptor | Homo sapiens (human) | 4.3 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 1.2199 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 3.843 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 3.0652 | |
| Thromboxane-A synthase | Homo sapiens (human) | 3.0594 | |
| Type-1 angiotensin II receptor | Homo sapiens (human) | 0.0405 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 1.2199 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdeen, S; Chapman, E; Chitre, S; Hoang, QQ; Johnson, SM; Park, Y; Ray, AM; Salim, N; Sivinski, J; Stevens, M; Washburn, A | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
2 other study(ies) available for tanshinone ii a and candesartan
| Article | Year |
|---|---|
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
Topics: Biological Products; Chaperonin 10; Chaperonin 60; Escherichia coli; Humans; Inhibitory Concentration 50; Protein Folding; Rafoxanide; Salicylanilides; Suramin | 2019 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |